Steroid News
News bot on steroids
FDA Panel Mulls Safety of Asthma Meds
[SIZE=-1]Washington Post, United States[/SIZE]
[SIZE=-1]The risks of two widely used asthma drugs outweigh their benefits for both children and adults, a U.S. Food and Drug Administration advisory panel said Thursday.[/SIZE]
[SIZE=-1]The health panel targeted GlaxoSmithKline's Serevent and Foradil, made jointly by Novartis AG and Schering-Plough, for restrictions, but it excluded Advair, Glaxo's biggest-selling drug in the class of medications known as long-acting beta-agonists. It also left alone a fourth such drug, AstraZeneca's Symbicort. [...][/SIZE]
[SIZE=-1]"This is an over-interpretation of the risk without adequate consideration of benefit," said Dr. Miles Weinberger, a professor of pediatrics at the University of Iowa. "However, there has been irresponsible marketing of the products, salmeterol and formoterol, and irresponsible prescribing by many physicians." [/SIZE]
[SIZE=-1]"Since most patients with chronic asthma can be controlled with inhaled steroids alone, using these more expensive combination formulations as first line is inappropriate but strongly encouraged by marketing practices" of drug makers, Weinberger said [/SIZE][SIZE=-1]...[/SIZE]
More...
[SIZE=-1]Washington Post, United States[/SIZE]
[SIZE=-1]The risks of two widely used asthma drugs outweigh their benefits for both children and adults, a U.S. Food and Drug Administration advisory panel said Thursday.[/SIZE]
[SIZE=-1]The health panel targeted GlaxoSmithKline's Serevent and Foradil, made jointly by Novartis AG and Schering-Plough, for restrictions, but it excluded Advair, Glaxo's biggest-selling drug in the class of medications known as long-acting beta-agonists. It also left alone a fourth such drug, AstraZeneca's Symbicort. [...][/SIZE]
[SIZE=-1]"This is an over-interpretation of the risk without adequate consideration of benefit," said Dr. Miles Weinberger, a professor of pediatrics at the University of Iowa. "However, there has been irresponsible marketing of the products, salmeterol and formoterol, and irresponsible prescribing by many physicians." [/SIZE]
[SIZE=-1]"Since most patients with chronic asthma can be controlled with inhaled steroids alone, using these more expensive combination formulations as first line is inappropriate but strongly encouraged by marketing practices" of drug makers, Weinberger said [/SIZE][SIZE=-1]...[/SIZE]
More...
